Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma

Bookmark and Share
Published: 17 Dec 2018
Views: 1001
Dr Habte Yimer - Texas Oncology, Tyler, USA

Dr Habte Yimer speaks to ecancer at ASH 2018 about the Lyra study, a phase II study that uses daratumumab (dara) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) to treat newly diagnosed and relapsed patients with multiple myeloma (MM).

He explains that PFS and OS results so far indicate that dara-CyBorD is comparable to dara-VMP.

Dr Yimer says this treatment might be particularly useful for patients with renal failure or if they are otherwise not a candidate for other treatment options.